{"brief_title": "Cervical Intraepithelial Neoplasm (CIN)-Warts Efficacy Trial in Women (Gardasil)(V501-013)(COMPLETED)", "brief_summary": "The primary purpose of the study is to determine if GARDASIL (V501) with four components is able to prevent cervical cancer, cervical dysplasia, including Cervical Intraepithelial Neoplasia (CIN)(Any Grade) and Adenocarcinoma In Situ (AIS), and genital warts.", "condition": "Genital Warts", "intervention_type": "Biological", "intervention_name": "Human Papillomavirus (HPV) 16 Monovalent", "description": "HPV 16 Monovalent vaccine, a 0.5 mL intramuscular injection given at Day 1, Month 2 and Month 6.", "arm_group_label": "3", "criteria": "Inclusion Criteria: - Female with an intact uterus with lifetime history of 0-4 sexual partners Exclusion Criteria: - Prior Human Papillomavirus (HPV) vaccination - Prior abnormal paps - History of genital warts", "gender": "Female", "minimum_age": "16 Years", "maximum_age": "23 Years", "healthy_volunteers": "Accepts Healthy Volunteers", "id": "NCT00092521.xml"}